{"id":"placebo-to-reformulated-raltegravir","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Raltegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the human genome, thereby halting HIV replication. This reformulated version maintains the same mechanism of action as the original formulation but with potentially improved pharmacokinetic properties.","oneSentence":"Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:01.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02131233","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"HIV Infection","enrollment":802}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Reformulated Raltegravir","genericName":"Placebo to Reformulated Raltegravir","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naive and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}